The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid, and Novartis AG are joining and committing resources to improve outcomes for people living with HR+/HER2- advanced breast care in low- and middle-income countries.
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.
